Clinical Trials Logo

Pancreatic Cancer clinical trials

View clinical trials related to Pancreatic Cancer.

Filter by:

NCT ID: NCT02449967 Withdrawn - Pancreatic Cancer Clinical Trials

HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Cancer

Start date: May 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction Angiography(DSA)for pancreatic cancer.

NCT ID: NCT02446379 Withdrawn - Pancreatic Cancer Clinical Trials

Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery

CLIO
Start date: n/a
Phase: N/A
Study type: Observational

This study will evaluate the performance of the EnLightTM and LightPathTM Imaging Systems in detecting tumour lesions in patients with gastric, pancreas, bile duct or duodenal cancer. EnLightTM will be used to detect positron emission and the LightPathTM system to detect Cerenkov Luminescence. Both are emitted by the Positron Emission Tomography (PET) agent. The study will also evaluate the patient safety and radiation safety of the EnLightTM, and the safety for the device operators and surgical staff of the LightPathTM Imaging System.

NCT ID: NCT02442739 Withdrawn - Depression Clinical Trials

Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers

Start date: August 15, 2016
Phase: Early Phase 1
Study type: Interventional

The primary purpose of this study is to see if it is safe to give patients with pancreatic or head and neck cancer a low dose of the FDA approved anesthetic drug ketamine at the same time they receive radiation and/or chemotherapy for their cancer treatment to prevent depression and its effects. Researchers would also like to see if giving ketamine at the same time as cancer treatment is practical and reasonably acceptable to the patient. New onset depression is highly frequent in those with head and neck cancer, and depression has many negative consequences for outcomes in those patients. Depression has been known to have greater incidence in pancreatic cancer patients than in patients with other malignancies. Therefore, investigators would also like to see if giving patients ketamine during their routine cancer treatment will prevent the onset of depression and its negative effects on cancer treatment outcomes, and also help with anxiety, pain, and quality of life. The study will also use a placebo to compare to the good and/or bad effects of ketamine. A placebo is not an active drug and it will be look the same as ketamine, as a liquid to be taken by mouth. Ketamine is approved by the U.S. Food and Drug Administration (FDA) as a general anesthetic by itself for some diagnostic and surgical procedures or combined with other general anesthetic agents. It has also been shown to reduce cancer pain. Ketamine is considered experimental in this study because it is not approved by the FDA for the prevention of depression.

NCT ID: NCT02366858 Withdrawn - Pancreatic Cancer Clinical Trials

Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures

Start date: October 2013
Phase: N/A
Study type: Interventional

The investigators hypothesis is that a 22 gauge needle can yield core tissue, obviating the need to use the 19 gauge needle for core tissue procurement.

NCT ID: NCT02159248 Withdrawn - Pancreatic Cancer Clinical Trials

Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation

Start date: March 2014
Phase: Phase 1
Study type: Interventional

The purposes of this study are to: - Evaluate the safety and toxicity of tolfenamic acid when used with gemcitabine and radiation therapy in patients with locally advanced or metastatic pancreatic cancer. - Determine the maximum-tolerated dose (MTD) of tolfenamic acid when used with gemcitabine and radiation in pancreatic cancer. - Characterize the pharmacokinetic profile of tolfenamic acid when used with gemcitabine and radiation. - Assess the anti-tumor response to tolfenamic acid when used with gemcitabine and radiation in patients with advanced pancreatic malignancies.

NCT ID: NCT02106871 Withdrawn - Pancreatic Cancer Clinical Trials

Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer

PCC
Start date: April 2014
Phase: Phase 1
Study type: Interventional

Investigation of the effects of daily sildenafil on patients with pancreatic or cholangiocarcinoma cancer undergoing treatment.

NCT ID: NCT01913275 Withdrawn - Pancreatic Cancer Clinical Trials

Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy

Start date: March 2006
Phase: N/A
Study type: Interventional

Periampullary carcinoma and carcinoma head of pancreas are common causes of obstruction at the lower end of the common bile duct. Whenever possible, surgical resection in the form of Whipple Pancreaticoduodenectomy (WPD) is the treatment of choice. However, this operation is associated with a substantial postoperative morbidity and mortality. With advances in surgical techniques and postoperative care there has been a decrease in the operative mortality. However, the postoperative morbidity remains high varying between 5%-64%. Of the various risk factors, the degree of jaundice as indicated by the serum bilirubin levels has been associated with an increased risk of complications. Preoperative biliary drainage has been tried to decrease the serum bilirubin levels and consequently decrease postoperative morbidity and mortality. Internal biliary drainage can be achieved by surgical cholecystojejunostomy or endoscopic bile duct stenting. Endoscopic stenting can be done as a day care procedure under conscious sedation, but involves insertion of a foreign body (stent), which results in introduction of bacteria into the bile and problems of postoperative infection. Also, endoscopic stenting before surgery may result in difficulty in dissecting around the common bile duct during the surgical procedure. While the surgical bilioenteric bypass has the advantage that no foreign body is inserted into the biliary tree and hence the likelihood of sepsis is low, it requires anesthesia and involves a surgical incision. There is no study comparing the outcomes of preoperative endoscopic and surgical drainage in patients undergoing pancraticoduodenectomy. We plan to compare the outcomes of preoperative endoscopic biliary drainage with surgical drainage in patients undergoing pancreaticoduodenectomy.

NCT ID: NCT01895790 Withdrawn - Pancreatic Cancer Clinical Trials

Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer

Start date: July 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This research is being done to assess the effects of pancreatic duct stenting on relief of obstructive pain (pain due to outflow obstruction of main pancreatic duct) caused by pancreatic cancer.

NCT ID: NCT01707758 Withdrawn - Pancreatic Cancer Clinical Trials

Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence

Start date: October 2012
Phase: N/A
Study type: Observational

The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.

NCT ID: NCT01598584 Withdrawn - Pancreatic Cancer Clinical Trials

Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer

Start date: June 2012
Phase: Phase 2/Phase 3
Study type: Interventional

Depression and anxiety accompany with advanced cancer. The effect of anti-anxiety depression has not evaluated in special cancers. Mirtazapine is a drug anti-anxiety depression and has a high risk increase weight. So the investigators assume Mirtazapine would not only improve the anxiety and depression of metastasis pancreas cancer but also would improve the appetite of such patients which would improve dyscrasia of pancreas cancer patients. The drug may improve the quality of life in advanced pancreatic cancer which is of short survival.